ILMN Stock Recent News

China announced a ban on Tuesday on imports of genetic sequencers from U.S. medical equipment maker Illumina , just minutes after U.S. President Donald Trump's additional 10% tariff on Chinese goods took effect.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Illumina, Inc. (NASDAQ:ILMN ) AGBT Investor Session Conference February 25, 2025 11:00 AM ET Company Participants Salli Schwartz - Head of Investor Relations Jacob Thaysen - Chief Executive Officer Steve Barnard - Chief Technology Officer Ankur Dhingra - Chief Financial Officer Conference Call Participants Subbu Nambi - Guggenheim Securities Dan Brennan - TD Cowen Dan Arias - Stifel Puneet Souda - SVB Securities Doug Schenkel - Wolfe Research Tycho Peterson - Jefferies LLC Patrick Donnelly - Citi Tejas Savant - Morgan Stanley Jack Meehan - Nephron Research Kyle Mikson - Canaccord Genuity Salli Schwartz Welcome. Thank you for your patience while we got started.

Illumina Collaborates with Broad Clinical Labs to set the standard for scalable single-cell research and accelerate discovery in areas such as disease modeling and drug development.

Company expands multiomics portfolio with new roadmap technologies spanning genomics, spatial, single cell, CRISPR, and methylation, as well as a new multimodal data analysis platform Built on Illumina's powerful sequencers, new, disruptive omics solutions surpass industry standards for quality, scale, accuracy, and replicability SAN DIEGO , Feb. 24, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) has unveiled a series of roadmap innovations, establishing the industry's largest portfolio of omics solutions and sequencing applications. The solutions – spanning genomics, spatial transcriptomics, single cell analysis, CRISPR technologies, epigenetics, and data analytics software – will enable researchers to derive breakthrough insights around the drivers of disease.

Longstanding partners bring together end-to-end workflows and leading CRISPRPerturb-seq technologies setting a standard for single-cell studies and enabling a 5billion single-cell atlas ecosystem within three years SAN DIEGO , Feb. 21, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in next-generation sequencing and array-based technologies, today announced a collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows.  Together, the longstanding partners will set the standard for scalable single-cell research and accelerate the development of a 5 billion cell atlas within the next three years.

Broad Institute to collaborate on flagship project tapping Illumina's new spatial technology At AGBT, customers will present data demonstrating unparalleled scale and sensitivity in research spanning pulmonary fibrosis, prostate cancer, and 3D reconstructions of mouse brains Company expands software portfolio to decode multimodal data with Illumina Connected Multiomics SAN DIEGO , Feb. 19, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced a new spatial technology program that will empower researchers to map complex tissues and understand cellular behavior at an unprecedented scale. Enabled on Illumina sequencers and a new multimodal analysis platform, Illumina's spatial technology delivers unbiased whole-transcriptome profiling with cellular resolution and high sensitivity.

SAN DIEGO , Feb. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that investors, analysts, and other interested parties can access a live webcast of its upcoming investor session at the AGBT conference.  The investor fireside chat will begin at 8:00am Pacific Time (11:00am Eastern Time) on Tuesday, February 25, 2025 and will feature Jacob Thaysen (Chief Executive Officer), Ankur Dhingra (Chief Financial Officer), and Steve Barnard (Chief Technology Officer).

ILMN, IQV and DXCM are leveraging AI advancements to drive innovation in genomics, clinical research and diabetes management.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.